Systena frontalis (Fabricius) (Coleoptera: Chrysomelidae) is a serious insect pest in nursery production. Insecticides are an important control tactic for S. frontalis adults to reduce economic losses associated with its injury.
View Article and Find Full Text PDFSystena frontalis (F.) (Coleoptera: Chrysomelidae) is a serious pest of ornamental shrubs in containerized ornamental plant nurseries in the central and eastern United States. Adult S.
View Article and Find Full Text PDFJ Am Soc Echocardiogr
November 2009
The authors describe left ventricular myocardial changes on transthoracic echocardiography in patients imaged within 72 hours of acute infarction. Endocardial separation from the mid myocardium, echocardiographic contrast penetration into the myocardium, and regional contrast swirling were observed. This case series also illustrates how contrast imaging may enhance recognition of early postinfarction remodeling.
View Article and Find Full Text PDFBackground: Before the widespread use of primary percutaneous coronary intervention (PCI) and glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa) left ventricular (LV) thrombus formation had been reported to complicate up to 20% of acute myocardial infarctions (AMI). The incidence of LV thrombus formation with these treatment modalities is not well known.
Methods: 92 consecutive patients with ST-elevation AMI treated with PCI and GP IIb/IIIa inhibitors underwent 2-D echocardiograms, with and without echo contrast agent, within 24-72 hours.
Background: Prompt detection of atherosclerosis (ATH) may profoundly impact therapy and patient outcome. During transthoracic echocardiography (TTE), subcostal views may suggest abdominal (ABD) aortic (AO) ATH, but this diagnosis may be inaccurate due to suboptimal images, which may in part relate to use of nonlinear probes. Therefore, we investigated the accuracy of TTE assessment of ABD AO ATH relative to transesophageal (TEE) AO images.
View Article and Find Full Text PDFThe safety of glycoprotein (GP) IIb/IIIa inhibitors has been well documented in clinical trials. Although these trials have included a broad patient population, the strict enrollment criteria may have resulted in exclusion of patients at a higher risk of bleeding complications. The authors conducted a retrospective chart review of 1020 consecutive patients who received GP IIb/IIIa inhibitors and underwent percutaneous coronary intervention in a large community hospital.
View Article and Find Full Text PDFThe safety of adjunct eptifibatide in the setting of rescue angioplasty (PTCA) with or without stenting after full-dose thrombolytic therapy is not well defined. Our study was undertaken to assess the risk of hemorrhagic complications following use of eptifibatide in patients undergoing rescue PTCA/stenting following failed thrombolysis. Clinical records of 43 consecutive patients (53% males) who received eptifibatide during rescue PTCA/stenting following full-dose fibrinolytic therapy were reviewed.
View Article and Find Full Text PDF